 "Initiate suitable prosecution steps against AstraZeneca management, pleads FMRI")
The U.S. Food and Drug Administration approved AstraZeneca Plc's combo treatment for a form of lung cancer in previously untreated patients, the drugmaker said on Monday.
The combo treatment has been approved in the United States for adult patients with extensive-stage small cell lung cancer, the company said.
The approval was based on results from a late-stage study in which the treatment showed a statistically significant improvement in overall survival in lung cancer patients when compared to standard of care, the company said.
Small cell lung cancer
